854267-89-3

Basic information

• Product Name: 1-(6-Chloropyridin-3-yl)cyclopropanecarbonitrile
• Synonyms: 1-(6-Chloropyridin-3-yl)cyclopropanecarbonitrile;1-(6-CHLORO-3-PYRIDINYL)-CYCLOPROPANECARBONITRILE;CYCLOPROPANECARBONITRILE, 1-(6-CHLORO-3-PYRIDINYL)-;1-(6-chloropyridin-3-yl)cyclopropane-1-carbonitrile
• CAS NO: 854267-89-3
• Molecular Formula: C9H7ClN2
• Molecular Weight: 178.61828
• Mol File: 854267-89-3.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• CAS DataBase Reference: 1-(6-Chloropyridin-3-yl)cyclopropanecarbonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(6-Chloropyridin-3-yl)cyclopropanecarbonitrile(854267-89-3)
• EPA Substance Registry System: 1-(6-Chloropyridin-3-yl)cyclopropanecarbonitrile(854267-89-3)

Safety Data

• Hazardous Substances Data: 854267-89-3(Hazardous Substances Data)

Usage

General Description

1-(6-Chloropyridin-3-yl)cyclopropanecarbonitrile is a chemical compound with the molecular formula C9H6ClN. It is a cyclopropanecarbonitrile derivative with a chloropyridine substituent at the 1-position. 1-(6-Chloropyridin-3-yl)cyclopropanecarbonitrile is used in the synthesis of pharmaceuticals and agrochemicals. It has potential applications in the field of medicinal chemistry and drug discovery due to its unique structure and properties. Additionally, it may also be used as an intermediate in the production of other organic compounds.

Upstream product

• 39891-09-3 (6-chloro-pyridin-3-yl)-acetonitrile 
• 106-93-4 ethylene dibromide 
• 107-04-0 1-Bromo-2-chloroethane 

Downstream Products

• 854267-90-6 1-(6-chloropyridin-3-yl)cyclopropanecarboxylic acid 

Relevant articles and documents

THIADIAZOLYL DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS

Disclosed herein are certain thiadiazolyl derivatives Formula (I): that inhibit DNA Polymerase Theta (Polθ) activity, in particular inhibit Polθ activity by inhibiting ATP dependent helicase domain activity of Polθ. Also, disclosed are pharmaceutical compositions comprising such compounds and methods of treating and/or preventing diseases treatable by inhibition of Polθ such as cancer, including homologous recombination (HR) deficient cancers.

NEW AZIRIDINE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE AS ACETYL-COA CARBOXYLASE INHIBITORS

The invention relates to new azetidine derivatives of the formula (I) wherein Ar1, Ar2, X, R, T and L are as defined in the description, to their use as medicaments, to methods for their therapeutic use and to pharmaceutical compositions containing them.

SUBSTITUTED 5-,6- AND 7-MEMBERED HETEROCYCLES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, AND THEIR USE

The present invention relates to compounds defined by formula I: wherein the variables A1, A2, Cy1 Cy2, Cy3, E, R1a, R1b, R2, R3, n, and Q are as defined herein, possessing valuable pharmacological activity. Particularly, the compounds are inhibitors of 11 β-hydroxysteroid dehydrogenase (HSD) 1 and thus are suitable for treatment and prevention of diseases which can be influenced by inhibition of this enzyme, such as metabolic diseases, in particular diabetes type 2, obesity, and dyslipidemia.